已收盘 02-06 16:00:00 美东时间
+0.070
+1.36%
This acquisition establishes Niagen Bioscience as the sole owner of the most comprehensive and defensible intellectual property portfolio in the NAD+ industryNiagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on
2025-12-22 21:34
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of Tru Niagen® Beauty, the first-ever
2025-11-13 21:44
今日重点评级关注:HC Wainwright & Co.:维持Caribou Biosciences"买入"评级,目标价从3美元升至9美元;HC Wainwright & Co.:上调CervoMed评级至"买入",目标价从11美元升至25美元
2025-11-06 09:55
Niagen Bioscience shares are trading higher after the company reported better-t...
2025-11-05 05:59
Niagen Bioscience (NASDAQ:NAGE) affirms FY2025 sales outlook from $124.496 million-$129.476 million to $124.496 million-$129.476 million vs $126.462 million estimate.
2025-11-05 05:03
The latest update is out from Niagen Bioscience ( ($NAGE) ). On October 6, 2025...
2025-10-07 04:34
Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced it has increased its full-year 2025 net sales outlook
2025-10-06 20:39
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Niagen Bioscience (NASDAQ:NAGE) with a Buy and raises the price target from $11 to $12.
2025-08-11 18:36
Niagen Bio shares are trading higher after reporting better-than-expected Q2 fi...
2025-08-07 05:28